Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in the UBS Virtual Ophthalmology Day 2024. Aziz Mottiwala, Chief Commercial Officer, will engage in a virtual fireside chat on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET.

Tarsus, a company focused on addressing unmet needs in eye care through proven science and new technology, will provide a live webcast of the presentation. Interested parties can access the webcast and additional information through the events section of the Tarsus website. A replay of the presentation will be available on the company's website within 48 hours and will be archived for a time.

This participation underscores Tarsus's commitment to revolutionizing treatment for patients, particularly in the field of ophthalmology.

IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET.

A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When is Tarsus Pharmaceuticals (TARS) participating in the UBS Virtual Ophthalmology Day 2024?

Tarsus Pharmaceuticals (TARS) is participating in the UBS Virtual Ophthalmology Day 2024 on Wednesday, October 2, 2024, at 6:00 a.m. PT / 9:00 a.m. ET.

Who will represent Tarsus Pharmaceuticals (TARS) at the UBS Virtual Ophthalmology Day 2024?

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals (TARS), will represent the company in a virtual fireside chat at the event.

How can investors access the Tarsus Pharmaceuticals (TARS) presentation at the UBS Virtual Ophthalmology Day 2024?

Investors can access a live webcast of the presentation through the events section of the Tarsus Pharmaceuticals website. A replay will be available within 48 hours and archived for a time.

What is the primary focus of Tarsus Pharmaceuticals (TARS)?

Tarsus Pharmaceuticals (TARS) focuses on addressing unmet needs and applying proven science and new technology to revolutionize treatment for patients, starting with eye care.